Fenofibrate

證據等級: L5

預測適應症: 7 個

Fenofibrate: From Dyslipidemia to Homozygous Familial Hypercholesterolemia

One-Sentence Summary

Fenofibrate is a PPARα agonist traditionally used to manage hypertriglyceridemia and mixed hyperlipidemia (dyslipidemia). The TxGNN model predicts it may also be effective for Homozygous Familial Hypercholesterolemia (HoFH), but this direction is currently supported by only 1 indirectly relevant clinical trial (testing a different drug in the same disease population) and 11 publications, none of which are direct fenofibrate RCTs in HoFH.

Quick Overview

Item	Content
Original Indication	Dyslipidemia (hypertriglyceridemia / mixed hyperlipoproteinemia) — inferred from supporting literature; no formal Norway label text available
Predicted New Indication	Homozygous Familial Hypercholesterolemia
TxGNN Prediction Score	99.91%
Evidence Level	L4
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, fenofibrate is a fibrate-class PPARα agonist, and its efficacy in dyslipidemia (hypertriglyceridemia, mixed hyperlipoproteinemia) has been proven; mechanistically, this profile is being evaluated for potential relevance to homozygous familial hypercholesterolemia.

Dyslipidemia and HoFH both fall under disorders of lipid metabolism, which is likely why the TxGNN model linked them. However, the pathophysiology differs substantially: HoFH results from a near-complete loss of LDL receptor (LDLR) function, whereas fenofibrate's core action — increasing lipoprotein lipase (LPL) activity and lowering ApoC-III — primarily reduces triglycerides and modestly raises HDL, with only limited effect on LDL-C.

Because HoFH patients require LDLR-independent treatment strategies (PCSK9 monoclonal antibodies, lomitapide, LDL apheresis), fenofibrate's mechanism has weak evidence for meaningful LDL-C reduction in this specific population. It may still have a role as adjunctive triglyceride control, but not as a core therapy — which is consistent with the model's own generated rationale for this candidate.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03510715	Phase 3	Completed	18	Evaluated alirocumab (a PCSK9 inhibitor, not fenofibrate) in children/adolescents with HoFH on LDL-C reduction over 12–48 weeks. Only the disease population overlaps; this is not direct evidence for fenofibrate.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
6593751	1984	Small trial	Pharmacological Research Communications	22 type II hyperlipoproteinemia patients treated with fenofibrate 300 mg/day; one patient with HoFH showed the greatest fall in total and LDL cholesterol among the cohort.
2042836	1991	Review	Annals of the New York Academy of Sciences	Reviews pharmacologic/surgical treatments for dyslipidemic children, noting fenofibrate among agents with variable success in familial hypercholesterolemia.
24734312	2014	Review/PK	Pharmacotherapy	PK interaction study of lomitapide (an approved HoFH drug) with commonly co-used lipid-lowering agents including fenofibrate.
24946816	2014	Review	Internal Medicine Journal	Reviews liver transplantation for HoFH and notes emerging lipid-lowering drug alternatives to LDL-apheresis.
37979722	2024	Review	Indian Heart Journal	States fenofibrate's most definite monotherapy indication is severe hypertriglyceridemia (>500 mg/dL) to prevent pancreatitis; modest cardiovascular benefit noted.
28437620	2017	Review/Guideline	Endocrine Practice	AACE/ACE clinical practice guideline for dyslipidemia management and cardiovascular disease prevention.
26432726	2015	Review	Indian Heart Journal	Reviews LDL-C reduction strategies including statins and PCSK9 inhibitors for severe hypercholesterolemia.
14620392	2003	Review	Pharmacotherapy	Reviews ezetimibe as a selective cholesterol absorption inhibitor, contextualizing non-statin LDL-lowering options.
9129869	1997	Review	Drugs	Pharmacology and therapeutic potential of atorvastatin in hyperlipidemia management.
35499807	2022	Review	Current Atherosclerosis Reports	Reviews dyslipidemia management in pregnancy; not specific to HoFH or fenofibrate.

Norway Market Information

Fenofibrate is currently not marketed in Norway (total authorizations: 0). No license records are available to summarize approved indications, dosage forms, or product names.

Safety Considerations

Please refer to the package insert for safety information. (No key warnings, contraindications, or drug interaction data are currently available in the evidence pack — TFDA/label warning data is flagged as a blocking data gap.)

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence for fenofibrate in HoFH is limited to preclinical/mechanistic-level data (L4) with no direct fenofibrate clinical trials in this population — the only registered trial evaluates a different drug (alirocumab) in the same disease group. Combined with fenofibrate's weak mechanistic fit for LDLR-independent disease and the drug's current non-marketed status in Norway, this candidate does not meet the threshold to proceed.

To proceed, the following is needed:

TFDA/Norwegian label warnings and contraindications (currently a blocking data gap)
Detailed mechanism of action (MOA) data from DrugBank
At least one fenofibrate-specific clinical trial or controlled study in a HoFH population
Formal Norway licensing/regulatory pathway assessment, since the drug is not yet marketed

Note: Within this evidence pack, rank 2 — hyperlipoproteinemia — has substantially stronger support (L1 evidence, multiple completed Phase 3 RCTs, recommendation: Proceed with Guardrails) and may warrant separate evaluation as a more viable repurposing candidate for this drug.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.